Trending Entertainment filem breaking news Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Trending Leisure filem breaking information Janssen Submits Biologics License Software to U.S. FDA Searching for Approval of Teclistamab for the Therapy of Sufferers with Relapsed or Refractory A number of Myeloma

RARITAN, N.J. – WEBWIRE – Friday, December 31, 2021 The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell…